Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12049736 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Tan M, et al. (2002) Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9, 993-1004 12049736
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S216-p - Cdc25C (human) ▲
Orthologous residues
Cdc25C (human): S216‑p, Cdc25C iso3 (human): S173‑p, Cdc25C (mouse): ‑, Cdc25C (frog): S287‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  MDA-MB435 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human

Y15-p - CDK1 (human) ▲
Orthologous residues
CDK1 (human): Y15‑p, CDK1 (mouse): Y15‑p, CDK1 (rat): Y15‑p, CDK1 (chicken): Y15‑p, CDK1 (fruit fly): Y15‑p
Characterization
 Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  breast, breast cell-breast, BT-474 (breast cell), MCF-7 (breast cell), MDA-MB435 (breast cell)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
PHOSPHATASE Cdc25C (human)
KINASE HER2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE HER2 (human) co-immunoprecipitation, transfection of inactive enzyme, genetic transfer of wild-type enzyme, genetic transfer of constitutively active upstream enzyme, inhibition of upstream enzyme, activation of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-HER2 decrease
heregulin increase
IgG no change compared to control
Downstream Regulation
 Effect of modification (process):  apoptosis, inhibited

Y1248-p - HER2 (human) ▲
Orthologous residues
HER2 (human): Y1248‑p, HER2 iso2 (human): Y638‑p, HER2 (mouse): Y1249‑p, HER2 (rat): Y1250‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heregulin increase

Y15-p - CDK1 (mouse) ▲
Orthologous residues
CDK1 (human): Y15‑p, CDK1 (mouse): Y15‑p, CDK1 (rat): Y15‑p, CDK1 (chicken): Y15‑p, CDK1 (fruit fly): Y15‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  MEF (fibroblast) [IGF1R (mouse)]
 Cellular systems studied:  cell lines
 Species studied:  mouse


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.